Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Synucleinopathy

Synucleinopathy — NIH Grants & Funding

Active and recent NIH-funded research on Synucleinopathy. Data from NIH RePORTER, last 36 months.

MONDO:0000510

NIH-funded research on Synucleinopathy

active grants

institutions

114

researchers

new in last 12 mo.

$137.4M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(81)

Basic ScienceRF1Active

Structure-function relationships in alpha-synuclein strain biology

Woerman, Amanda·COLORADO STATE UNIVERSITY·FORT COLLINS, CO

$2,674,385 (FY2025)

Synucleinopathy — NIH Grants & Funding

Basic Science(81)

Structure-function relationships in alpha-synuclein strain biology

How Serine-129 Phosphorylation Status Affects the Spreading of α-Synuclein Pathology in Vivo: a Study in Knock-in Animals

Decoding the BETA-arrestin2-LMBRD2 cascade in ALPHA-synuclein pathogenesis.

Synergistic Enhancement of ER proteostasis, trafficking, and lysosomes as treatments for Dementia with Lewy bodies and Parkinson’s disease-dementia

Role of N-terminal acetylation in alpha synuclein stability, function, and therapeutic targeting in synucleinopathies

Investigating physiologic and pathophysiologic connections between the Parkinson's disease protein alpha-synuclein and RNA binding proteins

MIF Nuclease actions in Synuclein Dementias

Neuroplasticity and the emergence of motor and cognitive deficits in prodromal synucleinopathy

Synucleinopathies – Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach

Region-Specific Vulnerability of the Lewy Body Dementia's Brain

Translational(10)

Immunologic and Imaging studies with TNF Therapy in Prodromal Synucleinopathies

Novel fibril-selective nanobody-based agents targeting intracellular and extracellular α-synuclein aggregates and prion-like propagation induced dementia

Defining The Substrates of Acyl Protein Thioesterase-1: Their Role in Modulating Alpha-Synuclein Toxicity

Advanced multiplexing technologies with innovative Dual-Channel Dark-FRET biosensors for dynamic monitoring of alpha-synuclein pathophysiology: From cellular to in vivo models

Fluorescent IRE sensor for synucleinopathy drug discovery

Heterochronic Blood Exchange Inhibits α?Synucleinopathy through Modulating Plasma Protein's Mediation on Pathological α?Synuclein Spreading

Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease

Circadian disruption as an accelerator of synucleinopathy

Immunotherapy for Synucleinopathies: Can Gut Microbiota Affect Efficacy?

A multiplexable in vivo perturbation toolkit to identify genes affecting neurodegeneration in a model of synucleinopathy

Clinical(9)

Mechanisms Underlying Heterogeneity of Cognitive Outcomes in Synucleinopathy

Clinical Trial Readiness for Multiple System Atrophy - Resubmission - 1

The cross-talk between a-Synucleinopathies and T cell immunity in ADRD

CSF Oligomeric α-synuclein targeted nano scavengers as a Parkinson's disease theranostic

An in vivo multiplex model to study gene-environment interaction in Parkinson's Disease

Effect of agent and host factors on alpha-synuclein strain pathogenesis

A randomized, double blind, placebo-controlled study to evaluate the impact of Nilotinib treatment on safety, tolerability, pharmacokinetics and biomarkers in Dementia with Lewy Bodies (DLB)

A new in vivo zebrafish model to study alpha-synuclein aggregation in Lewy Body Disease

Cognitive and Affective Network Dysfunction and Neuromodulation in Aging and Synucleinopathy

Epi / Nat. History(1)

Determining the Interacting Effects of GBA, SNCA, and APOE on a-Synuclein Pathology Severity in Dementia with Lewy Bodies and Parkinson's Disease

Gene/Cell Therapy(1)

Human Dopamine Grafts in Alpha-Synuclein Models of Parkinson Disease

Biomarker / Dx(11)

Detection of Prions

Biologically Novel Mouse Models of PD with Progressive Synucleinopathy and Early-Onset Tremor and Motor Deficits Responsive to L-DOPA

Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies

Understanding biomarkers of cognitive decline in Lewy body diseases

PET imaging of alpha-synuclein pathology

α-Synuclein strain properties are associated with diagnosis of and progression to Parkinson's disease with dementia

A transcriptomics-based approach to identify quantitative biomarkers for multiple system atrophy

A Diagnostic Test for Dementia with Lewy Bodies

Biomarkers of cognitive decline in Parkinson's Disease

Brainstem-based imaging biomarkers of premanifest synucleinopathy

Medical Device(3)

Development of a Blood-based Test for Identifying Synucleinopathy in Patients with Dementia

Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics

Astrocyte NLRP3 inflammasome activation in Parkinson's disease

Other(1)

Mechanisms of alpha-synuclein mediated inflammation in multiple system atrophy